EMA Authorised: Revlimid (lenalidomide) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The European Medicines Agency authorised Revlimid (lenalidomide) for multiple indications including multiple myeloma, mantle cell lymphoma, and myelodysplastic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes

Drugs mentioned

• Revlimid (lenalidomide)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma;Lymphoma, Mantle-Cell;Myelodysplastic Syndromes. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 05/06/2025